Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Opthea Limited (OPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.70-0.05 (-0.65%)
At close: 4:00PM EDT
Advertisement

Opthea Limited

650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399
http://www.opthea.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.MD, CEO & Exec. Director531.45kN/A1974
Ms. Karen Adams CPAVP of Fin. & Company Sec.701.33kN/AN/A
Ms. Annie LeeFin. & Operations Mang.N/AN/AN/A
Dr. Richard ChadwickHead of Intellectual PropertyN/AN/A1966
Dr. Michael GeromettaHead of Chemistry, Manufacturing & Controls Devel.N/AN/A1964
Dr. Ian LeitchDirector of Clinical ResearchN/AN/A1963
Dr. James GodingIndependent ConsultantN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Corporate Governance

Opthea Limited’s ISS Governance QualityScore as of September 26, 2021 is 4. The pillar scores are Audit: 7; Board: 4; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement